CAMBRIDGE, Mass., May 8, 2024 (Globe Newswire) — Spero Therapeutics, Inc. (NASDAQ: SPRO); The company, an asset-rich, clinical-stage biopharmaceutical company focused on identifying and developing new treatments for rare diseases and multidrug-resistant (MDR) bacterial infections, today reports financial results for the first quarter of 2024. The company announced that it would provide the latest information on its business. and Pipeline after market close on Wednesday, May 15th. The Company does not plan to host a conference call and plans to resume its quarterly results conference upon announcing its second quarter 2024 results.
About Spero Therapeutics
Headquartered in Cambridge, Massachusetts, Spero Therapeutics is a multi-asset, clinical-stage biopharmaceutical company focused on identifying and developing new treatments for rare diseases and multidrug-resistant (MDR) bacterial infections.
-
Spero Therapeutics is developing its wholly-owned lead product candidate, SPR720, as a novel oral first-line treatment for non-tuberculous mycobacterial pulmonary disease (NTM-PD), currently in a Phase 2A proof-of-concept study. We are proceeding. NTM-PD is a rare lung disease caused by nontuberculous mycobacterial infections.
-
Tebipenem HBr is an oral investigational drug in ongoing Phase 3 registration trials for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis. Spero has granted GSK an exclusive license to commercialize tebipenem HBr in all regions except certain Asian regions.
-
SPR206 is an innovative, investigational, IV-administered, direct-acting, next-generation polymyxin that has demonstrated antibiotic activity against MDR Gram-negative pathogens including carbapenem-resistant Enterobacteriaceae, Acinetobacter baumannii, and Pseudomonas aeruginosa in preclinical studies. I am. The FDA has approved an investigational new drug (IND) application to advance SPR206 into a Phase 2 clinical trial in participants with hospital-acquired or ventilator-associated bacterial pneumonia.
For more information, please visit: https://sperotherapeutics.com.
Investor information contact:
Ashley R. Robinson
LifeSci Advisors, LLC Managing Director
arr@lifesciadvisors.com
(617) 775-5956
Media inquiries: media@sperotherapeutics.com